---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007464"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:47:00.944624+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies releases case study showing CyPath Lung helps avoid biopsy in elderly patient

## Summary
- CyPath Lung test was negative for a 79-year-old woman with suspicious LDCT finding, supporting surveillance over invasive biopsy.
- Repeat CT scan in October 2025 showed nodule resolved, validating the conservative management decision.
- Test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.
- Case study highlights CyPath Lung's role in reducing unnecessary procedures in high-risk patients.

## SEC filing metadata
- accession: 0001493152-26-007464
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226007464/0001493152-26-007464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226007464/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007464
- JSON: https://secwatch.observer/filing/0001493152-26-007464.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.